Trial intelligence / Profile preview

NRX 195183 and Arsenic Trioxide in Untreated APL

NCT00670150Phase 2Withdrawn

Sponsor
University of Southern California
Start
May 2010
Primary completion
Aug 2010
Modality
Orthosteric Ligands
Countries
1
01

Overview

A Phase 2 trial of irx-5183 in acute promyelocytic leukemia (APL), sponsored by University of Southern California. Planned start May 2010; status: withdrawn.

02

Drugs

irx-5183
03

Conditions

acute promyelocytic leukemia (APL)

Beyond the preview

Go deeper on NCT00670150.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00670150.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call